---
title: "Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281187506.md"
datetime: "2026-03-31T12:32:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281187506.md)
  - [en](https://longbridge.com/en/news/281187506.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281187506.md)
---

# Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing

March 31 (Reuters) - IO Biotech Inc (IOBT.O) :

-   IO BIOTECH INC - FILES VOLUNTARY CHAPTER 7 BANKRUPTCY PETITION ON MARCH 31, 2026 - SEC FILING
-   IO BIOTECH INC - COMMON STOCKHOLDERS UNLIKELY TO RECEIVE PAYMENT OR DISTRIBUTION AFTER BANKRUPTCY - SEC FILING
-   IO BIOTECH INC - TERMINATES ALL EMPLOYEES AND OFFICERS INCLUDING CEO AND CFO - SEC FILING
-   IO BIOTECH INC - CHAPTER 7 TRUSTEE APPOINTMENT TRIGGERS DEFAULT UNDER EIB FINANCE CONTRACT FOR EUR22.5 MILLION - SEC FILING Source text: Further company coverage: (IOBT.O)

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IOBT.US](https://longbridge.com/en/quote/IOBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IOBTQ.US](https://longbridge.com/en/quote/IOBTQ.US.md)

## Related News & Research

- [INmune Bio Expands Cord Tissue License for CORDStrom Platform](https://longbridge.com/en/news/285278264.md)
- [Viridian eye disease drug benefits chronic patients in late-stage trial](https://longbridge.com/en/news/285192042.md)
- [Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway](https://longbridge.com/en/news/285244765.md)
- [Illumina Q1 revenue beats on demand for NovaSeq X](https://longbridge.com/en/news/284828330.md)
- [Summit's Q1 Net Loss Widens; Expects Patient Enrollment In Phase III ILLUMINE Study In Q2,2026](https://longbridge.com/en/news/284871928.md)